PTEN and acute lymphoblastic leukemia: Moreover, mutations in PTEN, particularly in patients with T-precursor ALL, may correlate with a heightened risk of relapse, potentially linking to resistance mechanisms against conventional treatment schemes, although this remains a subject of debate [13,14,15,16].